Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 2,336	$ 16,952
Available-for-sale investments	105,575	14,737
Other receivables	435	2,039
Prepaid expenses	5,223	1,803
Total current assets	113,569	35,531
Property and equipment, net	543	899
Right-of-use assets	1,267	2,083
Other assets	158	213
Total assets	115,537	38,726
Current liabilities:
Accounts payable	1,031	1,431
Accrued expenses	4,002	3,572
Current portion of operating lease liability	980	861
Total current liabilities	6,013	5,864
Long-term operating lease liability, net of current portion	398	1,378
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares – 0 as of December 31, 2021 and 2020, respectively
Common stock, $0.001 par value per share; 42,500,000 and 21,425,000 authorized shares as of December 31, 2021 and 2020, respectively; issued and outstanding shares – 27,793,035 and 11,018,954 as of December 31, 2021 and 2020, respectively	28	11
Additional paid-in capital	481,832	370,210
Accumulated other comprehensive loss	(263)	(43)
Accumulated deficit	(372,296)	(338,528)
Total aTyr Pharma stockholders’ equity	109,301	31,650
Noncontrolling interest in Pangu BioPharma Limited	(175)	(166)
Total stockholders' equity	109,126	31,484
Total liabilities and stockholders’ equity	$ 115,537	$ 38,726